LAS VEGAS, Jan. 8 /PRNewswire-FirstCall/ -- CardioVascular
BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two
additional hospitals in the United States opened for patient enrollment for
its ACORD Phase II clinical trial for the treatment of severe coronary heart
disease. The sites are
Mercy Hospital Fairfield (Ohio) and The Christ Hospital in Cincinnati, Ohio were first to open for enrollment in early September, and are working in collaboration to screen and treat patients in the trial. They treated their first patient in support of the trial in mid November 2008.
CVBT now has five sites that are open for enrollment and intends to announce additional sites as they open for screening patents.
About CardioVascular BioTherapeutics
CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit http://www.cvbt.com.
Media Contact: Allison Caplan, CardioVascular BioTherapeutics, Inc. (702) 839-7200, email@example.com Investor Contact: Amy Montano Gordon, CardioVascular BioTherapeutics, Inc. (702) 839-7220, firstname.lastname@example.org
|SOURCE CardioVascular BioTherapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved